Short communication

Improved efficacy of fluoxetine in increasing hippocampal 5-hydroxytryptamine outflow in 5-HT_{1B} receptor knock-out mice

Isabelle Malagie, Denis J. David, Pascale Jolliet, René Hen, Michel Bourin, Alain M. Gardier

Laboratoire de Neuropharmacologie UPRES EAD MENRT, Faculté de Pharmacie IFR-ISIT Institut de Signalisation et d’Innovation Thérapeutique, Université Paris-Sud, Tour D1 2ème etage 5 rue 1-B.Clement, 92296, Châtenay-Malabry cedex, France

Laboratoire de Pharmacologie, Faculté de Médecine, Université de Nantes, F44035, Nantes cedex 1, France

Center for Neurobiology and Behavior, Columbia University, New York, NY 10032, USA

Received 14 January 2002; received in revised form 8 April 2002; accepted 12 April 2002

Abstract

To test for the contribution of the 5-HT_{1B} receptor subtype in mediating the effects of fluoxetine, a selective serotonin reuptake inhibitor (SSRI), we used intracerebral in vivo microdialysis in awake, freely moving 5-HT_{1B} receptor knock-out mice. We show that a single systemic administration of fluoxetine (1, 5 or 10 mg/kg, i.p.) increased extracellular serotonin levels [5-HT]_{ext} in the ventral hippocampus and frontal cortex of wild-type and mutant mice. However, in the ventral hippocampus, fluoxetine, at the three doses studied, induced a larger increase in [5-HT]_{ext} in knock-out than in wild-type mice. In the frontal cortex, the effect of fluoxetine did not differ between the two genotypes. The region-dependent response to fluoxetine described here in mutants confirms data we recently reported for another SSRI, paroxetine. These data suggest that 5-HT_{1B} autoreceptors limit the effects of selective serotonin reuptake inhibitors on dialysate 5-HT levels at serotonergic nerve terminals located mainly in the ventral hippocampus. Alternative mechanisms, e.g., changes in 5-HT transporter and/or 5-HT_{1A} receptor density in 5-HT_{1B} receptor knock-out mice could also explain these findings.

Keywords: Antidepressant drug, 5-HT_{1B} autoreceptor; Microdialysis, intracerebral; Knock-out mouse; Fluoxetine; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective

1. Introduction

The main hypothesis regarding pathogenesis of major depression involves a deficiency in the brain serotonergic function. In support of this hypothesis, selective serotonin reuptake inhibitors (SSRI), by blocking the transporter of serotonin (5-hydroxytryptamine, 5-HT), increase its synaptic availability, thus improving the central serotonergic neurotransmission. However, activation of somatodendritic 5-HT_{1A} and nerve terminal 5-HT_{1B} autoreceptors by endogenous 5-HT seems to limit the therapeutic efficacy of these antidepressant drugs following their acute administration (Gardier et al., 1996). The 5-HT_{1B} receptor localized in the central nervous system on presynaptic nerve terminals of serotonergic neurons are called autoreceptors because they are involved in a local inhibitory control of 5-HT release (Engel et al., 1986; Maura et al., 1986; Göthert et al., 1987; Pinedy et al., 1995; Trillat et al., 1997).

Recently, we used intracerebral in vivo microdialysis to investigate the contribution of 5-HT_{1B} autoreceptors in mediating the effects of a selective serotonin reuptake inhibitor, paroxetine (Malagie et al., 2001). Experiments were performed in awake, freely moving mice lacking 5-HT_{1B} receptors (5-HT_{1B} knock-out; Saudou et al., 1994). We demonstrated that a single systemic administration of paroxetine induced a larger increase in extracellular serotonin levels [5-HT]_{ext} in the ventral hippocampus of 5-HT_{1B} receptor knock-out mice than that observed in wild-type mice. In the frontal cortex, the effect of paroxetine was larger in mutants than in wild-type mice at the 1 mg/kg dose, but not at 5 mg/kg. These results were confirmed by using a receptor antagonist strategy in wild-type mice showing that the blockade of 5-HT_{1B} receptor with the mixed 5-HT_{1B/1D} receptor antagonist (N-[4-methoxy-3-(4-methylpiperazin-1-
yl)phenyl]-2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxamide) GR 127935, potentiated the effect of paroxetine on [5-HT]_{ext} in the ventral hippocampus, but not in the frontal cortex. These data demonstrate that the activation of 5-HT_{1B} autoreceptors by endogenous 5-HT limit the effects of paroxetine on dialysate 5-HT levels particularly in the hippocampus. To know whether this property could be extended to other molecules, we compared here the effects of a single systemic administration of another selective serotonin reuptake inhibitor, fluoxetine (1, 5 or 10 mg/kg, i.p.) on [5-HT]_{ext} in 5-HT_{1B} selective serotonin reuptake inhibitor versus wild-type mice using the same experimental conditions than those we previously used for paroxetine.

2. Materials and methods

2.1. Drugs

Fluoxetine hydrochloride (1, 5 and 10 mg/kg; Alchemy, Italy) was dissolved in water in a volume of 10 ml/kg and administered intraperitoneally (i.p.). The animals were habituated to intraperitoneal injection before injection of the drugs or saline solution.

2.2. Animals

The founders of the wild-type and mutant colonies used in the present study were the product of heterozygous matings made at the animal facility of Columbia University. These founders were shipped to France and their offspring were bred and reared in independent colonies. Wild type and 5-HT_{1B} receptor knock-out mice were male mice, 9–11 weeks old, obtained from a pure 129/Sv genetic background. Group-housed mice were kept in standard cages on a 12-h light/12-h dark cycle with light onset at 7 h. The mice were tested between 10:00 and 16:00 during the light phase. Only mice with probes confined to either the ventral hippocampus or the frontal cortex were used for subsequent data analysis.

2.3. Microdialysis

Concentric dialysis probes were made of cuprophan fibers and constructed as described previously (Malagie et al. 2002).
All probes present an active length of 1.6 and 2 mm for the frontal cortex and ventral hippocampus, respectively (× 0.30 mm OD). Animals were anaesthetized with chloral hydrate (400 mg/kg, i.p.) and were implanted with two probes, cemented in place, one in the right frontal cortex and the other in the left ventral hippocampus, according to a mouse brain atlas (Franklin and Paxinos, 1997) [coordinates: from bregma (in mm), frontal cortex, A = +2.0, L = +1.2, V = −1.6; ventral hippocampus, A = −2.8, L = −3.0, V = −4.0 (A, anterior; L, lateral; and V, ventral)]. The animals were allowed to recover from the surgery overnight. The next day, ≈ 20 h after surgery, the probes were continuously perfused with an artificial cerebrospinal fluid (composition in mM: NaCl 147, KCl 3.5, CaCl$_2$ 1.26, MgCl$_2$ 1.2, NaH$_2$PO$_4$ 1.0, NaHCO$_3$ 25.0, pH 7.4 ± 0.2) at a flow rate of 1.3 μl/min using a CMA/100 pump (Carnegie Medicin, Stockholm, Sweden). Dialysate samples were collected every 15 min in small Eppendorf tubes and were analyzed for 5-HT by a high-performance liquid chromatography apparatus (XL-ODS, 4.6 × 7.0 mm, particle size 3 μm; Beckman) coupled to an amperometric detector (1049A, Hewlett-Packard, Les Ulis, France) as previously described (Malagie et al., 2001). Usually four fractions were collected to obtain basal values (means ± S.E.M.) before peripheral administration of the drugs. The limit of sensitivity for 5-HT was ≈ 0.5 fmol/sample (signal-to-noise ratio = 2).

2.4. Data analysis and statistics

Data (mean ± S.E.M.) in Figs. 1 and 2 were standardized by transforming dialysate 5-HT concentrations into percentages of baseline values based on averages of the first four fractions uncorrected for in vitro probe recovery. Groups of wild-type (n = 32) and mutant (n = 29) mice were exposed to saline or fluoxetine. Area under the curve (AUC; mean ± S.E.M.) values calculated for the amount of 5-HT outflow collected during the 0–180 min period from the ventral hippocampus and frontal cortex are expressed as percentage of basal values. Statistical analyses were performed using the computer software StatView 4.02 (Abacus Concepts, Berkley, CA, USA). For each brain structure, a two-way analysis of variance (ANOVA) on AUC values was performed, with the drug treatment (saline, fluoxetine 1, 5 or 10 mg/kg) and the mouse genotype (wild-type or knock-out) as main factors. The significance level was set at P < 0.05.

![Frontal Cortex Diagram](image)

**Fig. 2.** Effects of fluoxetine on extracellular 5-HT levels in the frontal cortex of wild-type (WT) and 5-HT receptor knock-out (KO) mice. Data are means ± S.E.M. of extracellular 5-HT levels expressed as percentages of baseline in wild-type (white symbols, A) and KO (black symbols, B) mice following exposure to saline (□ or ■), fluoxetine 1 mg/kg (○ or ◼), 5 mg/kg (△ or ▲) and 10 mg/kg (○ or ◼), respectively (n = 6–9 determinations per group). Drugs were administered i.p. at t0 (black arrow). Basal values (in fmol/20 μl): 4.1 ± 0.4 (n = 29) and 4.05 ± 0.44 (n = 28) in the ventral hippocampus of wild-type and KO mice, respectively. (C) Area under the curve (AUC; mean ± S.E.M.) values calculated for the amount of 5-HT outflow collected during the 0–180 min post-treatment period are expressed as percentage of basal values. *P < 0.05, **P < 0.01 and ***P < 0.001 relative to the corresponding control group; #P < 0.05 and ##P < 0.01 relative to the corresponding fluoxetine-treated group.
3. Results

Basal extracellular levels of 5-HT did not differ significantly between the two strains of mice [mean ± S.E.M. of the various groups of mice studied, in fmol/20 μl, n = number of determinations per group: 2.65 ± 0.32 (n = 31) and 2.2 ± 0.14 (n = 29) in the ventral hippocampus of wild-type and knock-out mice, respectively]. A single systemic administration of fluoxetine (1, 5 or 10 mg/kg, i.p.), dose-dependently increased [5-HT]ext in the two brain regions studied in wild-type and 5-HT1B receptor knock-out mice. However, in the ventral hippocampus, fluoxetine at the two doses studied induced a larger increase in [5-HT]ext in 5-HT1B receptor knock-out than in wild-type mice (Fig. 1A–C). A two-way ANOVA (genotype × treatment) on AUC values revealed significant genotype factor [F(1,53) = 9.50, P < 0.01], treatment factor [F(3,53) = 65.26, P < 0.001] and a significant interaction [F(3,53) = 3.86, P = 0.05]. The effect in mutants was significantly greater than in wild-type mice for the intermediate and the highest fluoxetine doses studied ([†P < 0.01]. In the frontal cortex, a two-way ANOVA (genotype × treatment) on AUC values revealed a significant treatment factor [F(3,53) = 30.16, P < 0.001], but no significant genotype factor [F(1,53) = 0.006, P = 0.94], and no interaction [F(3,53) = 0.81, P = 0.49] (Fig. 2A–C). Thus, in the frontal cortex, fluoxetine-induced increases in [5-HT]ext were similar in wild-type and knock-out mice at the three doses studied. Fluoxetine induced a region-dependent effect, the largest increase in dialysate 5-HT being observed in the ventral hippocampus of mutant mice.

4. Discussion

A systemic administration of a single dose of fluoxetine (1–10 mg/kg), increased [5-HT]ext values in the two brain regions studied in both mice’ genotypes. The results obtained in wild-type mice confirm the dose-dependent effect we have previously found following the systemic effect of fluoxetine. Taken together, these results demonstrate that terminal 5-HT1B autoreceptors limit the effects of selective serotonin reuptake inhibitors in the dorsal raphe nucleus versus dorsal raphe nucleus projection system. It is thus conceivable to propose that combining a selective serotonin reuptake inhibitor with a 5-HT1A receptor antagonist may improve the efficacy of the selective serotonin reuptake inhibitor in the dorsal raphe nucleus- innervated brain areas such as the frontal cortex, striatum and globus pallidus, while co-administration of a selective serotonin reuptake inhibitor with a 5-HT1B receptor antagonist may improve the efficacy of the selective serotonin reuptake inhibitor in the median raphe nucleus- innervated brain areas such as the ventral hippocampus, hypothalamus and medial septum. It is now very important to identify which one of these brain regions is implicated in the etiology of depression and/or plays a predominant role in the mediation of the therapeutic effects of selective serotonin reuptake inhibitors. If two non-overlapping and perhaps functionally distinct brain 5-HT systems may exist, then a tri-therapy combining (a selective serotonin reuptake inhibitor + a 5-HT1A receptor antagonist + a 5-HT1B receptor antagonist) could help to increase further the extracellular levels of 5-HT in a very large number of brain regions. However, the resulting activation of postsynaptic 5-HT receptors by endogenous 5-HT may explain the therapeutic efficacy of these antidepressant drugs. The answer to the following question “which of the fifteen known 5-HT receptor subtypes mediate this therapeutic effect?” is still a matter of a very important debate.

Another key question regarding constitutive knock-out animals, and here with mice lacking the 5-HT1B receptor subtype (5-HT1B receptor knock-out), deals with adaptive compensatory changes that may have occurred in the functional activity of somatodendritic 5-HT1A receptors during the development of these mutants. We have not tested this hypothesis in detail by using microdialysis or behavioral tests in our laboratory, but several studies have already been reported. Thus, results of a ligand binding study using [3H]8-hydroxy-2-(di-N-propylamino)tetralin ([3H]8-OH-DPAT) indicated that the number of 5-HT1A receptors is the same in mutant and WT mice (unpublished data-Saudou et al., 1994). In vitro/in vivo studies have already evaluated the functional activity of 5-HT1A receptors in 5-HT1B receptor knock-out mice, and homogenous results have been obtained: it has been found that 5-HT1A receptors do not adapt in 5-HT1B receptor knock-out mice (Ase et al., 2001). In addition, in these mutants, no changes in the spontaneous...
firing of the raphe 5-HT neurons, or in the potency of the 5-HT_{1A} receptor agonist, 8-OH-DPAT, to inhibit these cells have been found (Evrard et al., 1999). By contrast, in our laboratory, we recently assayed for decrease in body temperature induced by an acute subcutaneous injection of 8-OH-DPAT (Gardier et al., 2001). We found a higher efficacy of 8-OH-DPAT in inducing hypothermia in 5-HT_{1B} receptor knock-out compared to wild-type mice suggesting that an adaptive thermoregulatory process involving the functional activity of somatodendritic 5-HT_{1A} receptors is indeed altered in mutant mice lacking 5-HT_{1B} receptors. The development of regional compensations after genetic deletion of 5-HT_{1B} receptors has been suggested in a recent microdialysis study showing a decreased sensitivity of 5-HT_{1A} receptors in the ventral hippocampus in 5-HT_{1B} receptor knock-out mice (Knobelman et al., 2001). The authors suggest a potential desensitization of 5-HT_{1A} receptors in the median raphe nucleus of 5-HT_{1B} receptor knock-out mice. Altogether, whether or not compensatory changes in the efficacy of 5-HT_{1A} receptors would have occurred in 5-HT_{1B} receptor knock-out mice must be further investigated by using additional neurochemical or functional tests.

Previous data suggested interactions between the plasma membrane 5-HT transporter (5-HTT) and 5-HT_{1B} receptors (Daws et al., 2000). 5-HTT is up- or down-regulated in 5-HT_{1B} receptor knock-out mice depending on the brain region studied (Ase et al., 2001). For example, the density of [³H]citalopram binding was decreased in parts of the basal ganglia and thalamus of these mutants. The reduced number of uptake sites might contribute to enhance 5-HT neurotransmission in these brain regions under physiological conditions. By contrast, the density of 5-HTT was increased in the ventral hippocampus of 5-HT_{1B} receptor knock-out mice. This latter change was correlated with a 5-HT hyperinnervation in this brain region of mutants: this regional selectivity of 5-HT hyperinnervation may partly explain our microdialysis data obtained under pharmacological conditions in mutants following administration of paroxetine and fluoxetine. A larger number of uptake sites might be targeted and blocked by a selective serotonin reuptake inhibitor, thus leading to a higher efficacy of these drugs in increasing extracellular levels of 5-HT in the ventral hippocampus, but not in the frontal cortex suggesting that 5-HT_{1B} autoreceptors limit the effects of selective serotonin reuptake inhibitors on dialysate 5-HT levels at serotonergic nerve terminals in the ventral hippocampus. The results highlight the crucial need for more selective 5-HT_{1B} receptor antagonists to be tested in human. Such drugs will help us to know whether or not we may expect clinical benefits in depressed patients using a combined administration of a selective serotonin reuptake inhibitor with presynaptic 5-HT_{1B} receptor antagonists (see Hjorth et al., 2000 for a review).

Acknowledgements

We thank Paula Pestana for technical assistance. This work was supported by a ‘Jeune Équipe’ award (JE 92-372) from the ‘Ministère de l’Enseignement Supérieur et de la Recherche’ (to AMG).

References


